The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Blueprint Medicines; Merrimack
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack
Consulting or Advisory Role - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Daiichi Sankyo; EMD Serono; Epizyme; Erasca, Inc; G1 Therapeutics; Ignyta; Janssen; Merrimack; Michael J. Hennessy Associates; Mirati Therapeutics; Novartis; OncLive; Pfizer; PharmaMar; Polaris; Roche; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie; Adaptimmune; Bayer; Epizyme; GlaxoSmithKline; Ignyta; Janssen; Novartis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Novartis
First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
 
George D. Demetri
No Relationships to Disclose
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Lilly; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Arcus Biosciences; AstraZeneca/MedImmune; Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; FLX Bio; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Tempest Therapeutics; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Dominic W. Lai
Employment - AbbVie
 
Huibin Yue
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Sreeneeranj Kasichayanula
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Scott Gulbranson
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
James Purcell
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Melinda Myzak
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Randy Robinson
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Victor Manuel Villalobos
Consulting or Advisory Role - Abbvie; Agios; Epizyme; Ignyta; Janssen; Lilly; Novartis
Travel, Accommodations, Expenses - Epizyme; GenMab; Janssen; Lilly; Xencor
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro BioTX (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BioInvent (Inst); Birdie Bio (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Forbius (Inst); HBM Partners (Inst); Ignyta (Inst); Immunome (Inst); Immunome (Inst); Jazz Pharmaceuticals (Inst); Mekanistic Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Ridgeway (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Aminex (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie Biomedical (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Kiromic (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Symphogen (Inst); Syndax (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)